HSCT

The MIST Phase 2 clinical trial, supporting the potential of hematopoietic (blood cell-producing) stem cell transplant (HSCT) to significantly slow disability progression in highly active relapsing-remitting multiple sclerosis (RRMS) patients, has received a Distinguished Clinical Research Achievement Award from the Clinical Research (CR) Forum. Five years after the transplant, most…

Blood Stem Cell Transplant Better than DMTs at Reducing Risk of Disease Progression in RRMS Here’s more evidence that hematopoietic stem cell transplant (HSCT) works better than some disease-modifying therapies (DMTs) at reducing multiple sclerosis (MS) progression. In this study, only three of 52 patients in the…

Autologous hematopoietic stem cell transplant is better than disease-modifying therapies (DMT) at reducing the risk of disease progression in patients with relapsing-remitting multiple sclerosis (RRMS), results from the MIST clinical trial show. The study “Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression…

There is some good news about stem cell therapy. A just-published study concludes that one form of human stem cell therapy is more effective at treating multiple sclerosis than the best of the MS medications being used currently. The not-so-good news is that approval of this…

Phoebe Scopes was the first international patient to receive Hematopoietic Stem Cell Transplantation (HSCT) therapy for multiple sclerosis in Moscow. In this fourth, and last, part of her story, we join Phoebe on her return home to the London. Ian: What is your post-HSCT MS state from getting home…

Last week, I introduced you to Phoebe Scopes, the very first MS patient from another country to undergo hematopoietic stem cell transplantation (HSCT) in Moscow. Today, in Part 2,  we pick up the story of the 46-year-old who lives in London. Ian: So, you had done lots of research. How…

Doesn’t time fly? It seems only yesterday that I was preparing to go to Moscow, yet tomorrow will be three weeks since my return. I have written enough about my experiences at the A.A. Maximov center so, today, we’ll take a look at how HSCT progresses, step by step. The…

My neurologist calls Lemtrada “HSCT lite.”  She says that not only is the drug able to reduce exacerbations and limit the overall progression of multiple sclerosis, it’s actually reversed some symptoms in some of her patients.   I guess I’m going to find out if she’s right about…

A high fraction of patients with multiple sclerosis (MS) who underwent a transplant with their own bone marrow stem cells after immunosupression therapy, show no signs of disease activity after treatment, according to a new study. The results were presented in a talk, “Clinical experience in aggressive multiple sclerosis treatment with…

Virtually all the talk about availability of HSCT1 as an MS treatment includes the need to travel long distances to other countries, but U.K. residents can receive the treatment in London, avoiding the journey overseas. What’s more, it is provided through the country’s social National Health Service (NHS) so, like…

News that the U.S. Food and Drug Administration (FDA) is to hold a public hearing next month to consider greater oversight of stem cell clinics operating in the country is as welcome as it is late. I say “late” because, while the regulators have been twiddling their fingers,…

News that scientists in the U.S. are working to find a new pre-HSCT treatment to carry out stem cell transplants without the need for chemotherapy, as published in Multiple Sclerosis News Today, leaves me with mixed feelings. While such a development could potentially be great news and an…

An entry in the comments section of Multiple Sclerosis News Today caught my attention a couple of weeks ago, and peaked my interest. It was a personal tale of one woman’s journey from being paralyzed and told that her condition was “between you and God” to being able to walk again, thanks to HSCT.

As interesting as it can be for patients with MS who hear about work being done to find the causes of multiple sclerosis, what we really want to see is research that is carried out to find a cure. Nothing more, nothing less. Of course, the development of new treatments…

When talking about how treatments affect MS life expectancy, it’s wrong to leave out HSCT. Sorry, but it’s just plain wrong. How can anyone write a supposedly authoritative article about MS and life expectancy, talk about modifying how the disease affects people who have it, yet totally ignore potentially the…

Geoff Flynn, 42, was diagnosed with multiple sclerosis (MS) two and a half years ago. As unsettling as that diagnosis was, more troubling — both then and now — were the five long years of struggle it took for him to get a proper evaluation as to the cause of his neurological…

Australian authorities are alerting Multiple Sclerosis patients to the risk of unproven stem cell treatments that are being performed both in the country and overseas, after the recent death of a woman in Russia undergoing a controversial treatment for the disease. The continued marketing campaigns to…

Multiple Sclerosis (MS) is a devastating disease for many who become afflicted with the disease’s progressive form, often in the prime of their lives, with no cure and when the effectiveness of established MS treatment is so often disappointing. Discouragement can lead to pinning premature hope on unproven therapies…